ObjectiveHealth has announced the launch of ObjectiveScreen, an AI feasibility and recruitment platform that seeks to provide patient identification, prequalification, and retention.
Powered by ObjectiveHealth’s cloud-based, AI and ML algorithms, ObjectiveScreen allows clinical trial sites to connect directly with patient electronic health records (EHRs). Patient health risks are stratified against evidence-based physiologic and molecular biomarkers so users can identify in the most qualified candidates for specific clinical trials.
Each time an EHR is linked, ObjectiveScreen’s algorithms analyze the health data, updating its clinical knowledge base while qualifying patients for the specific trials.
In addition to EHR analysis, ObjectiveScreen can review other patient data, including risk factors and demographic data such as age, gender, ethnicity and socioeconomic status, which can help identify candidates who may not have a diagnosis.
By linking with a healthcare provider’s scheduling application, users of ObjectiveScreen can arrange prescreen visits. ObjectiveScreen’s texting and calling capabilities allow clinical trial site users to communicate directly with patients about appointment reminders and rescheduling options. Users can also monitor patients over multiple visits and recommend new studies if patients did not qualify for a previous trial.
ObjectiveHealth Launches ObjectiveScreen, an Artificial Intelligence-Powered Feasibility and Recruitment Platform to Optimize Clinical Trial Performance. (2023, June 8). Business Wire.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.